1	ARTICLE
2	
3	Improved Detection of Decreased Glucose Handling Capacities via Novel
4	Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var
5	
6	Hikaru Sugimoto, ¹ Ken-ichi Hironaka, ² Tomoaki Nakamura, ³ Tomoko Yamada, ⁴ Hiroshi
7	Miura, ⁵ Natsu Otowa-Suematsu, ⁴ Masashi Fujii, ^{2,6} Yushi Hirota, ⁴ Kazuhiko Sakaguchi, ⁴
8	Wataru Ogawa, ^{4*} and Shinya Kuroda ^{1,2*}
9	
10	¹ Department of Biochemistry and Molecular Biology, Graduate School of Medicine, The
11	University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
12	² Department of Biological Sciences, Graduate School of Science, The University of Tokyo,
13	7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
14	³ Department of Diabetes and Endocrinology, Akashi Medical Center, 743-33 Okubo-cho
15	Yagi, Akashi, Hyogo 674-0063, Japan
16	⁴ Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University
17	Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
18	⁵ Department of Diabetes and Endocrinology, Takatsuki General Hospital, 1-3-13
19	Kosobe-cho, Takatsuki, Osaka 569-1192, Japan
20	⁶ Department of Mathematical and Life Sciences, Graduate School of Integrated Sciences for
21	Life, Hiroshima University, 1-3-1 Kagamiyama, Higashi-hiroshima City, Hiroshima
22	739-8526, Japan
23	
24	*Corresponding authors: Wataru Ogawa, ogawa@med.kobe-u.ac.jp; and Shinya Kuroda,
25	skuroda@bs.s.u-tokyo.ac.jp
26	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 ABSTRACT

28 Background

29 Efficiently detecting impaired glucose control abilities is a pivotal challenge in public health.

30 This study assessed the utility of relatively easy-to-measure continuous glucose monitoring

31 (CGM)-derived indices in estimating glucose handling capacities calculated from

32 resource-intensive clamp tests.

33

34 Methods

We conducted a prospective, single-center, observational cohort study of 64 individuals without prior diabetes diagnosis. The study utilized CGM, oral glucose tolerance test, and hyperglycemic and hyperinsulinemic-euglycemic clamp tests. We validated CGM-derived indices characteristics using an independent dataset and mathematical model with simulated data.

40

41 Findings

A novel CGM-derived index, AC_Var, was significantly correlated with insulin sensitivity (r 42 = -0.31; 95% CI: -0.52 to -0.06), insulin clearance (r = -0.31; 95% CI: -0.54 to -0.06), and 43 disposition index (DI) (r = -0.31; 95% CI: -0.52 to -0.07) calculated from clamp tests. 44 AC_Var was also significantly correlated with insulin resistance (r = 0.48; 95% CI: 0.23 to 45 0.68) in an independent dataset. Multivariate analyses indicated AC_Var's contribution to 46 predicting reduced blood glucose control abilities independent from conventional 47 CGM-derived indices. The prediction model's accuracy utilizing CGM-measured glucose 48 standard deviation and AC_Var as input variables, with clamp-derived DI as the outcome, 49 closely matched that of predicting clamp- from OGTT-derived DI. Mathematical simulations 50 51 also underscored AC_Var's association with insulin clearance and DI.

53 Interpretation

- 54 CGM-derived indices, including AC_Var, can be useful for screening decreased blood
- 55 glucose control ability. We developed a web application that calculates these indices
- 56 (<u>https://cgm-ac-mean-std.streamlit.app/</u>).
- 57

58 Funding

- 59 The Japan Society for the Promotion of Science KAKENHI, CREST, Japan Science and
- 60 Technology Agency, and Uehara Memorial Foundation.
- 61 (250/250 words)
- 62
- 63 Keywords
- 64 Continuous glucose monitoring, oral glucose tolerance test, clamp test, disposition index,
- 65 insulin clearance

67 INTRODUCTION

Pre-diabetes (pre-DM), a condition in which blood glucose controlling mechanisms are 68 slightly disrupted, is a high-risk condition for the development of type 2 diabetes mellitus 69 (T2DM) and its associated complications.¹ Approximately 5–10% of patients with pre-DM 70 develop T2DM annually,^{1,2} with up to 70% eventually developing T2DM.^{1,3} Despite lower 71 72 blood glucose levels in pre-DM compared to T2DM, individuals with pre-DM are at elevated risk of chronic kidney disease⁴ and cardiovascular disease,⁵ which are common complications 73 of diabetes. However, preventive measures through pharmaceutical or lifestyle interventions 74 can impede the progression to T2DM and mitigate complications.^{1,6,7} Consequently, pre-DM 75 screening followed by targeted interventions has demonstrated cost-effectiveness.⁸ 76 77 Optimal methods for detecting the decreased ability to control blood glucose,

however, have yet to be established. Hemoglobin A1c (HbA1c) and fasting blood glucose 78 (FBG) have been recommended for screening for pre-DM, but they lack precision for 79 prediabetes screening and even their combination has a diagnostic sensitivity of only about 80 60%.⁹⁻¹¹ The 2-h oral glucose tolerance test (OGTT) has long been the gold standard 81 diagnostic method for pre-DM and T2DM.¹² However, the cost, time, patient inconvenience, 82 and lack of reproducibility of the OGTT make it impractical for patient care.¹² Moreover, 83 these indices lack information on glycemic variability and changes in glucose levels 84 throughout the day, which are relevant to T2DM complications.^{13,14} Insulin sensitivity and 85 insulin secretion impairment precede T2DM development, with insulin resistance emerging 86 years prior and decreased β -cell function already present in pre-DM.¹ Although 87 hyperinsulinemic-euglycemic and hyperglycemic clamp tests have been the gold standards 88 for assessing insulin sensitivity and insulin secretion,¹⁵ their resource intensiveness impedes 89 practicality in screening. Consequently, the development of more accurate and accessible 90 methods for detecting reduced glucose control abilities constitutes a pressing public health 91 92 challenge.

93	Continuous glucose monitoring (CGM) has emerged as a promising avenue for
94	identifying individuals with reduced glucose handling capacity. ¹⁶⁻¹⁸ CGM-derived indices
95	identify individuals who are not identified as pre-DM by FBG, HbA1c, or OGTT, but who
96	have high levels of postprandial glucose, a characteristic of pre-DM and even T2DM. ¹⁹ A
97	CGM-derived index has demonstrated the ability to identify individuals with a high risk of
98	progressing to T2DM. ²⁰ Some CGM-derived indices also correlate with insulin secretion,
99	insulin sensitivity, or the disposition index (DI). ^{19,21–24} While various glycemic variability
100	indices derived from CGM have been reported, their relationship to glucose handling
101	capacity and their potential for identifying individuals with reduced glucose handling,
102	particularly in a population predominantly composed of healthy individuals, remain unclear.
103	Here, we assessed previously established CGM-derived indices ^{19,25} and introduced
104	two novel indices (AC_Mean and AC_Var) based on autocorrelation function of glucose
105	levels. By examining the correlation between these indices and indices calculated from
106	OGTT or clamp tests, we found that AC_Mean and AC_Var were significantly correlated
107	with insulin clearance or the DI, unlike the other CGM-derived indices. In addition,
108	multivariate analyses indicated that CGM-derived indices, including AC_Mean and AC_Var,
109	contributed to the prediction of decreased blood glucose control abilities. A mathematical
110	model with simulated data also indicated that AC_Mean and AC_Var were associated with
111	insulin clearance and the DI.

112

113 **METHODS**

Subjects and measurements 114

This study was conducted in accordance with the Declaration of Helsinki and its amendments, 115 and was approved by the ethics committee of Kobe University Hospital (Approval No. 1834; 116 Kobe, Japan). Written informed consent was obtained from all subjects. Study participants 117 who had no previous diagnosis of diabetes and were over 20 years old were recruited from 118

Kobe University Hospital (Hyogo, Japan) from January 2016 to March 2018. Exclusion
criteria were: 1) taking medications that affect glucose metabolism (e.g., steroids, β blockers);
2) patients with psychiatric disorders; 3) pregnant or breast-feeding women; and 4) deemed
unfit for any other reason by attending physicians.

The study participants initially underwent a 75-g OGTT in the morning after an overnight fast. Following the OGTT, they wore a CGM device (iPro; Medtronic, Minneapolis, MN, USA) for more than 72 h. Within 7 days after the OGTT, the participants underwent a consecutive hyperglycemic and hyperinsulinemic-euglycemic clamp test. Detailed procedures for the OGTT, consecutive hyperglycemic and hyperinsulinemic-euglycemic clamp, and CGM can be found in Supplementary Text 1.

129 A total of 70 participants were initially enrolled. One participant taking a β blocker, two participants with missing CGM data, two participants with protocol deviation, and one 130 participant with missing OGTT and/or clamp data were excluded from the analysis. 131 Consequently, data from 64 participants were used in the analysis (Fig. S1). The sample size 132 of 64 participants closely aligned with the cohort of 57 individuals investigated in a previous 133 134 study, where statistically significant correlations between CGM-derived indices and the ability to regulate blood glucose were demonstrated.¹⁹ Of note, with a type I error of 0.05, a 135 power of 0.8, and an expected Spearman correlation coefficient of 0.35, a sample size of 66 136 (Bonett and Wright's method) or 64 (Caruso and Cliff's method) was required to detect a 137 significant difference from zero in the correlation coefficient. This sample size estimation 138 was performed using SPSS version 29 (SPSS Inc.). 139

140

141 Subjects and measurements of a previously reported dataset

142 We also performed an analysis using publicity available data sets of CGM (Dexcom G4

143 CGM System; Dexcom, Fort Lauderdale, FL, USA), OGTT, and steady state plasma glucose

144 (SSPG) test outcomes from a previously reported study.¹⁹ The participants of that study,

recruited from the San Francisco Bay Area, had no previous diagnosis of diabetes.¹⁹ Among the study subjects (32 females and 25 males), 5, 14, and 38 individuals met their criteria of "type 2 diabetes" (HbA1c \geq 6.5%, FBG \geq 126 mg/dL, or 2-h glucose during 75-g OGTT \geq 200 mg/d), "pre-diabetes" (HbA1c > 5.7% and < 6.5%, FBG 100–125 mg/dL, or 2-h glucose during 75-g OGTT 140–199 mg/dL) and "normoglycemia" (glucose-related parameters below the diagnostic thresholds for pre-diabetes).¹⁹

151

152 CGM-derived parameters

153 CGM_Mean and CGM_Std represent the mean and standard deviation of glucose values

154 measured by CGM, respectively. CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE,

155 ADRR, MVALUE, and MAG were calculated using EasyGV software.²⁵ Here, we

introduced novel indices, the mean (AC_Mean) and the variance (AC_Var) of the

autocorrelation function of glucose values at lags 1–30 with a lag of 5 min. While

autocorrelation function has been used to analyze this type of time series data,^{26,27} it has not

been thoroughly investigated to date. AC_Mean and AC_Var used in analyzing blood

160 glucose levels after consuming standardized meals¹⁹ were calculated from the autocorrelation

function at lags 1–10, as we had CGM data available for only 2.5 h after standardized meals
were consumed.

DTW_Low, DTW_Mod, and DTW_Sev are previously proposed CGM-derived indices that represent the dysregulation of glycemia.¹⁹ These indices were calculated by a previously reported method.¹⁹ In brief, the time series data of CGM were fragmented into sliding windows of 2.5 h, with a 75% overlap. Then, by applying spectral clustering, three clusters of glucose patterns (low, moderate, and severe) were identified, and the fraction of time in each category was defined as DTW_Low, DTW_Mod, and DTW_Sev, respectively.

169

170 Calculation of clinical indices

- 171 Insulinogenic index (I.I):
- 172 Ratio of the increment of immunoreactive insulin (IRI) to that of plasma glucose at 30 min
- after the onset of the OGTT.
- 174 Composite index:
- 175

$[10000/\sqrt{\text{FPG} \times \text{FIRI} \times \text{G} \times \text{I}}],$

- where FPG, FIRI, G, and I are fasting plasma glucose, fasting IRI, mean blood glucose levels,
- and mean serum IRI concentrations during the OGTT, respectively.
- 178 Oral DI:
- 179 Product of the composite index and the ratio of the area under the insulin concentration curve
- 180 from 0 to 120 min to that for plasma glucose from 0 to 120 min, without using the data
- 181 measured at 90 min, in the OGTT.
- 182 AUC_IRI:
- 183 Incremental area under the IRI concentration curve from 0 to 10 min during the
- 184 hyperglycemic clamp.
- 185 Insulin sensitivity index (ISI):
- 186 The mean glucose infusion rate during the final 30 min of the clamp (mg/kg/min) divided by
- both the plasma glucose (mg/dL) and serum insulin (μ U/mL) levels at the end of the clamp
- and then multiplying the resulting value by 100.
- 189 Clamp DI:
- 190 The product of AUC_IRI and ISI.
- 191 Metabolic clearance rate of inulin (MCRI):
- 192 Ratio of insulin infusion rate to the steady-state plasma insulin concentration during the
- 193 hyperinsulinemic-euglycemic clamp test.
- 194
- 195 Mathematical model estimating insulin sensitivity, secretion, and clearance

196 To estimate insulin sensitivity, insulin secretion, and insulin clearance from clamp tests, we

197 constructed a mathematical model of the feedback loop that links glucose and insulin as

198 shown in a previous study²⁸ as follows:

199
$$\frac{dG}{dt} = \text{flux } 1 - \text{flux } 2 + \text{flux } 3 - \text{flux } 4 + \text{influx } G = k_1 Y - k_2 G + \frac{k_3}{k_8 + I} - k_4 GI + f_1(t)$$

200
$$\frac{dI}{dt} = \text{flux } 6 - \text{flux } 7 + \text{influx } I = k_6 X - k_7 I + f_2(t)$$

201
$$\frac{dY}{dt} = -\operatorname{flux} 1 + \operatorname{flux} 2 = -k_1 Y + k_2 G$$

202
$$\frac{dX}{dt} = \text{flux } 5 - \text{flux } 6 = k_5 Y - k_6 X$$

where the variables G and I denote blood glucose and insulin concentrations, respectively. The fluxes, influx G and influx I denote glucose and insulin infusions, respectively. These fluxes were estimated using a previously reported method.

For each of the 64 subjects, the parameters of the model to reproduce the time course 206 were estimated by a meta-evolutionary programming method to search the minimum globally, 207 208 followed by application of the nonlinear least squares technique to search the minimum locally, as previously described.²⁹ Each parameter of the model for serum glucose and insulin 209 concentration was estimated in the range from 10^{-4} to 10^{4} . For these methods, the parameters 210 were estimated to minimize the objective function value, which is defined as residual sum of 211 the square (RSS) between the actual time course obtained by clamp analyses and the model 212 trajectories. RSS used in the model for serum glucose and insulin concentration was given by 213 the following equation: 214

215
$$\operatorname{RSS} = \frac{n_I}{n_G + n_I} \sum_{i=1}^{n_G} [G(t_i) - G_{\operatorname{sim}}(t_i)]^2 + \frac{n_G}{n_G + n_I} \sum_{i=1}^{n_I} [I(t_i) - I_{\operatorname{sim}}(t_i)]^2,$$

where n_G and n_I are the total numbers of time points of measuring blood glucose and insulin, respectively, and t_i is the time of i-th time point. G(t) is the time-averaged blood glucose concentration within the time range (t - 5) min to t min with every 1-min interval, I(t) is the blood insulin concentration at t min. $G_{sim}(t)$ and $I_{sim}(t)$ are simulated blood

glucose and insulin concentrations, respectively. Blood glucose and insulin concentrations of
each subject were normalized by dividing them by the respective maximum value. The

- numbers of parents and generations in the meta-evolutionary programming were 400 and
- 4000, respectively.

224 Mathematical model used for simulating the characteristics of AC_Mean and AC_Var

In simulating the characteristics of AC_Mean and AC_Var, we used a simple and stable

226 model,³⁰ which can be written as follows:

227
$$\frac{dG}{dt} = -k_{\rm glu}G - k_{\rm sen}IG + k_{\rm pro} + f$$

228
$$\frac{dI}{dt} = \frac{k_{\text{sec}}}{k_{\text{tim}}} \int_{t-k_{\text{tim}}}^{t} G \, ds - k_{\text{cle}} I$$

where the variables *G* and *I* denote blood glucose and insulin concentrations, respectively. Parameter values reported as the averages for healthy subjects were as follows:³⁰

231
$$k_{glu} = 0.0226, k_{sen} = 5.64 \times 10^{-5}, k_{pro} = 1.93,$$

232
$$k_{\text{sec}} = 0.074, k_{\text{tim}} = 14.9, k_{\text{cle}} = 0.1262.$$

We simulated how 24-h profiles of *G* changed as $k_{sec}k_{sen}$ and k_{cle} , which correspond to the DI and insulin clearance, respectively, were changed from one-half to twice as large as the values. Five mg/dL/min glucose was applied for 10 min at 6-, 12-, and 18-h as the external input of glucose *f*. We also calculated the AC_Mean and AC_Var from *G* added

with zero-mean gaussian white noise with variances of 0.25, 0.5, or 1.

238

239 Prediction models and statistical analyses

240 In this study, we investigated the predictive performance of CGM-derived indices for

assessing the decline in blood glucose control ability across five main methodologies:

242 multiple linear regression, partial least squares (PLS) regression, least absolute shrinkage

- 243 operator (LASSO) regression, random forests, and logistic regression. Of note, these
- 244 prediction models were conducted as post hoc analyses. The input variables for these models

consisted of 27 variables: body mass index (BMI), abdomen circumference (ACir), body fat
percentage, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol
(TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), FBG, HbA1c, CGM_Mean, CGM_Std, CONGA, LI,
JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, MAG, DTW_Mod,
DTW_Sev, AC_Mean, and AC_Var. This modeling was conducted using scikit-learn, a
python-based tool kit.

The predictive performance assessment of multiple linear regression included 252 measures such as the coefficient of determination (R^2) , the adjusted coefficient of 253 determination (Adj R^2), and Akaike information criterion (AIC). The multicollinearity of the 254 255 input variables was estimated by the variance inflation factor (VIF). PLS regression was conducted to estimate the importance of the input variables in predicting the DI. The variable 256 importance in projection (VIP) scores,³¹ which were generated from PLS regression, were 257 used for estimating the importance of the input variables. Lasso regression is a kind of linear 258 regression with L1 regularization.^{32,33} The optimal regularization coefficients, lambda, were 259 based on leave-one-out cross validation. For multiple linear regression, PLS regression, 260 LASSO regression, and logistic regression, z-score normalization was performed on each 261 input variable. 262

Random forest is an ensemble learning method, which generates classification 263 decision trees by selecting subsets of input predictor variables randomly.³⁴ The study 264 employed 300 decision trees with Gini as the criterion for determining the best splits. The 265 predictive performance of random forests was assessed using accuracy and F1 score based on 266 leave-one-out cross-validation. The importance of the input variables in predicting glycemic 267 anomaly is based on the permutation and the feature importance function of the random forest 268 function. Boruta³⁵ was also used to test whether the input variables is usable for the 269 270 prediction.

271	Associations between indices were assessed using Spearman's correlation test, and
272	correlation coefficients were reported with 95% confidence intervals (Cis) through bootstrap
273	resampling. The number of resamples performed to form the bootstrap distribution was set at
274	10000. $P < 0.05$ was considered statistically significant. Benjamini-Hochberg's multiple
275	comparison test was also performed with a significance threshold of $Q < 0.05$.
276	Hierarchical clustering analysis was also conducted using a method that combines
277	Euclidean distance measure and Ward linkage. It was adopted after Z score normalization.
278	Comparisons among individuals in each cluster were performed by analysis of variance
279	followed by Tukey's honestly significant difference test.
280	
281	RESULTS
282	Autocorrelation of glucose levels fluctuations
283	In this study, our primary objective was to devise novel CGM-derived metrics that represent
284	the glucose handling capacity of the living body. To achieve this, we conducted CGM, an
285	OGTT, and a consecutive hyperglycemic and hyperinsulinemic-euglycemic clamp test in
286	individuals without prior diabetes diagnosis, enabling us to focus on early indicators of
287	reduced blood glucose control abilities.
288	We focused on the autocorrelation of glycemic fluctuation pattern, in particular, the
289	mean (AC_Mean) and the variance (AC_Var) of the autocorrelation function at lags 1–30
290	with the length of the lag for 5 min, given that glucose levels were measured every 5 min
291	with the CGM device (Figs. 1 and S2). Figure 1 shows the autocorrelation function of
292	glycemic fluctuation pattern in two representative subjects (Subjects #13 and #46), both of
293	whom were categorized as normal glucose tolerance (NGT), but had different clamp DI
294	values: 65.7 for Subject #13 and 11.5 for Subject #46.
295	For individuals with slower fluctuations in blood glucose levels, such as Subject #13,

the autocorrelation function displayed a slower rate of decrease with increasing lag (AC_ 296

Mean: 0.62, AC Var: 0.049). By contrast, subjects with more rapid glucose fluctuations, such 297 as Subject #46, exhibited a relatively swift decrease in autocorrelation function as the lag 298 increased (AC Mean: 0.24, AC Var: 0.12). It is noteworthy that although Subject #46 had a 299 lower clamp DI than Subject #13, the mean (CGM_Mean) and standard deviation 300 (CGM Std) of glucose values were also lower in Subject #46 (CGM Mean: 95; CGM Std: 301 16) than in Subject #13 (CGM Mean: 107; CGM Std: 18). Moreover, given the definition 302 formula for the autocorrelation function, the autocorrelation function would not change if 303 calculated from blood glucose levels standardized to a mean of 0 and a variance of 1, 304 indicating a possibility that AC_Mean and AC_Var can possess characteristics that differ 305 from the average or the variability of glucose levels. 306 307 Given these findings, we hypothesized that these indices might possess some information about underlying glucose regulatory abilities that are not discernible through 308 conventional measures such as OGTT or the mean and standard deviation of blood glucose 309 levels. Consequently, our primary research objective was to ascertain the association between 310 AC_Mean and AC_Var and glucose handling capacities, such as the DI and insulin clearance. 311 312 Of note, the DI and insulin clearance reportedly reflect glucose dysregulation well and predict the development of future T2DM beyond FBG and the plasma glucose concentration at 120 313 min during the OGTT (PG120).^{36,37} 314

315

Relationship between indices from CGM and those from OGTT or clamp tests

317 We compared AC_Mean and AC_Var with indices obtained from OGTT or clamp tests to

thoroughly assess the potential of these indices in estimating a decline in blood glucose

control ability (Figs. 2A and S3). In this study, CGM, OGTT, and clamp tests were

performed on 52 NGT, 9 impaired glucose tolerance (IGT), and 3 T2DM individuals (Table

S1). PG120, I.I., composite index, and oral DI were calculated from the OGTT. AUC_IRI,

ISI, and clamp DI were calculated from clamp tests. Additionally, k_4 , k_5 , and k_7 were

calculated using a previously established mathematical model.²⁹ PG120 is the plasma glucose 323 concentration at 120 min during OGTT. I.I., AUC_IRI, and k_5 correspond to insulin 324 secretion. Composite index, ISI, and k_4 correspond to insulin sensitivity. k_7 corresponds to 325 insulin clearance. DI is the product of insulin sensitivity and insulin secretion. Of note, we 326 refrained from employing multiple testing corrections encompassing all pairwise 327 comparisons in Figure 2A due to the interdependent nature of the conducted tests; we 328 analyzed various indicators that represent the same abilities, aiming to confirm the 329 meaningful correlations observed. 330

AC_Mean exhibited a statistically significant correlation with k_7 (r = 0.28; 95% CI: 331 0.04 to 0.50). AC_Var displayed statistically significant correlations with the oral DI (r = -332 333 0.28; 95% CI: -0.51 to -0.02), clamp DI (r = -0.31; 95% CI: -0.52 to -0.07), k_4 (r = -0.31; 95% CI: -0.52 to -0.06), and k_7 (r = -0.31; 95% CI: -0.54 to -0.06). Since we were testing 334 two indices, AC_Mean and AC_Var, we also applied the Benjamini-Hochberg's multiple 335 comparison test for each comparison, resulting in Q < 0.05 for these comparisons, validating 336 the significance of the identified relationships among these indices. To further validate the 337 relationships among these indices, we also investigated the relationships among AC_Mean, 338 AC_Var, k_4k_5 (corresponding to the clamp DI) and MCRI (corresponding to insulin 339 clearance). AC_Mean exhibited a statistically significant correlation with k_4k_5 (r = 0.29; 340 95% CI: 0.05 to 0.50). AC_Var displayed statistically significant correlations with k_4k_5 (r = 341 -0.29; 95% CI: -0.50 to -0.05) and MCRI (r = -0.33; 95% CI: -0.55 to -0.08). Additionally, 342 AC_Mean and AC_Var calculated from different lags were also significantly correlated with 343 k_7 , oral DI, and clamp DI (Fig. S4). Collectively, we conclude that AC_Mean and AC_Var 344 are associated with the DI or insulin clearance. 345

For comparison, we also assessed commonly used indicators such as FBG and HbA1c, which have been recommended for pre-DM screening.^{9–11} Moreover, we examined CGM-derived basic features such as mean (CGM_Mean) and standard deviation (CGM_Std)

as well as CGM-derived indices, DTW_Low, DTW_Mod, and DTW_Sev. These indices
have been shown to identify populations with decreased ability to control blood glucose
within populations primarily composed of individuals categorized as having NGT.¹⁹
DTW_Low, DTW_Mod, and DTW_Sev were calculated using a previously reported
method:¹⁹ low DTW_Low and high DTW_Sev indicate high glucose concentration and
variability and glucose dysregulation.

The indices that exhibited significant correlations with AC_Mean or AC_Var differed from those significantly correlated with FBG, HbA1c, or other indices derived from CGM data; the other indices were not significantly correlated with all of the oral DI, clamp DI, k_4 , and k_7 . By contrast, FBG, HbA1c, or the other CGM-derived indices were significantly correlated with PG120, I.I., and the composite index, where AC_Mean and AC_Var exhibited no significant correlations.

361

362 Estimation of the decreased ability to control blood glucose by combining CGM-derived 363 indices

Based on these findings, we hypothesized that a more accurate identification of individuals 364 with disrupted glucose regulation could be achieved by combining AC_Mean and AC_Var 365 with conventional indices. To test this hypothesis, we investigated the relationship among 366 AC Var, DTW_Sev, diabetes diagnosis, and clamp DI – an indicator of glycemic disability 367 and a predictor of T2DM³⁸ (Fig. 2B). Due to a significant correlation between AC_Mean and 368 AC_Var (r = -0.74; 95% CI: -0.85 to -0.60) (Fig. S3), we focused on AC_Var. AC_Var was 369 not significantly correlated with DTW_Sev (r = 0.06; 95% CI: -0.20 to 0.32). In subjects 370 with T2DM, both AC_Var and DTW_Sev were relatively high. Some subjects with high 371 values of AC_Var and DTW_Sev were diagnosed with NGT or IGT, but their clamp DI was 372 relatively low (Fig. 2B, *1). Some subjects had low DTW_Sev and low clamp DI (Fig. 2B, 373 374 *2), and others had low AC_Var and low clamp DI (Fig. 2B, *3). In these subjects, either

AC_Var or DTW_Sev was relatively high, suggesting a potential for combined use to
enhance accuracy in identifying individuals with impaired glucose control.

Theoretically, dynamic time warping, an algorithm that is employed to calculate 377 DTW_Sev, aligns time series data globally and may not fully account for autocorrelated 378 structure information.³⁹ Consequently, DTW Sev is mainly affected by the mean and the 379 variance of glucose levels.^{40,41} On the other hand, AC Var is calculated from autocorrelation 380 of glucose levels and autocorrelation is not affected by the mean and the variance of levels 381 given its definition formula. Collectively, these rationales also indicate that DTW_Sev and 382 AC Var can have different aspects of glucose characteristics and that a combination of these 383 two indices may be useful in estimating glucose handling capacities. 384

385 To further explore the efficacy of this combination, we conducted clustering analysis based on these indices (Fig. 2C). The sum of DTW_Low, DTW_Mod, and DTW_Sev was 1, 386 DTW_Low was excluded from this analysis. We divided the subjects into four groups based 387 on the relatedness of the indices: cluster \$1 mainly contained subjects with low DTW_Sev 388 and low AC_Var, cluster \$2 mainly contained subjects with low DTW_Sev and relatively 389 390 high AC_Var, cluster \$3 mainly contained subjects with relatively high DTW_Sev and low AC_Var, and cluster \$4 mainly contained subjects with relatively high DTW_Sev and 391 relatively high AC_Var. Subjects in cluster \$3 had statistically significantly lower oral DI 392 than those in cluster \$1 (Fig. 2D), and subjects in cluster \$2 had statistically significantly 393 lower clamp DI than those in cluster \$1, suggesting that subjects with high DTW_Sev 394 (cluster \$3) or high AC_Var (cluster \$2) have glycemic disabilities. As expected, subjects in 395 cluster \$4 had statistically significantly lower oral DI and clamp DI than those in cluster \$1 396 (Fig. 2D). 397

We also conducted multiple regression analyses among oral DI, clamp DI, and the CGM-derived indices (Table 1). *R*² of the models that predicted oral DI and clamp DI from DTW_Mod, DTW_Sev, and AC_Var were 0.24 and 0.14, respectively. AC_Var had an

401	independent negative correlation with oral DI and clamp DI that was statistically significant
402	($P = 0.029$ and $P = 0.010$, respectively), suggesting that AC_Var contributes to the prediction
403	of DI independently of DTW_Mod and DTW_Sev. AC_Var also had a negative correlation
404	with clamp DI that was statistically significant ($P = 0.048$) independently of CGM_Std
405	(Table 1C), which was also significantly correlated with clamp DI (Fig. 2A). R^2 , the
406	adjusted coefficient of determination (Adj R^2), and the AIC of the model that predicted clamp
407	DI from CGM_Std and AC_Var were 0.18, 0.15, and 583, respectively. Of note, R^2 , Adj R^2 ,
408	and AIC of the model that predicted clamp DI from oral DI were only 0.15, 0.14, and 583,
409	respectively. Collectively, we conclude that combining AC_Var with conventional
410	CGM-derived indices can increase the accuracy of predicting a decreased ability to control
411	blood glucose.
412	
413	Predicting DI from CGM, single-point blood tests, and physical measurement-derived
415	
414	indices
414	indices
414 415	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the
414 415 416	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the
414415416417	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the purpose of this study was to estimate glucose intolerance from relatively easy-to-measure
 414 415 416 417 418 	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the purpose of this study was to estimate glucose intolerance from relatively easy-to-measure indices, we included only CGM-derived indices, indices from a single blood test, and those
 414 415 416 417 418 419 	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the purpose of this study was to estimate glucose intolerance from relatively easy-to-measure indices, we included only CGM-derived indices, indices from a single blood test, and those from physical measurements as the input variables, as follows: CGM_Mean, CGM_Std,
 414 415 416 417 418 419 420 	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the purpose of this study was to estimate glucose intolerance from relatively easy-to-measure indices, we included only CGM-derived indices, indices from a single blood test, and those from physical measurements as the input variables, as follows: CGM_Mean, CGM_Std, CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, MAG,
 414 415 416 417 418 419 420 421 	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the purpose of this study was to estimate glucose intolerance from relatively easy-to-measure indices, we included only CGM-derived indices, indices from a single blood test, and those from physical measurements as the input variables, as follows: CGM_Mean, CGM_Std, CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, MAG, DTW_Mod, DTW_Sev, AC_Mean, AC_Var, TC, TGs, LDL-C, HDL-C, FBG, HbA1c, BMI,
 414 415 416 417 418 419 420 421 422 	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the purpose of this study was to estimate glucose intolerance from relatively easy-to-measure indices, we included only CGM-derived indices, indices from a single blood test, and those from physical measurements as the input variables, as follows: CGM_Mean, CGM_Std, CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, MAG, DTW_Mod, DTW_Sev, AC_Mean, AC_Var, TC, TGs, LDL-C, HDL-C, FBG, HbA1c, BMI, ACir, body fat percentage, SBP, and DBP.
 414 415 416 417 418 419 420 421 422 423 	indices To predict DI, which reflects glycemic disability and has been suggested as a predictor of the development of T2DM, ³⁷ we conducted multiple linear regression analyses. Since the purpose of this study was to estimate glucose intolerance from relatively easy-to-measure indices, we included only CGM-derived indices, indices from a single blood test, and those from physical measurements as the input variables, as follows: CGM_Mean, CGM_Std, CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, MAG, DTW_Mod, DTW_Sev, AC_Mean, AC_Var, TC, TGs, LDL-C, HDL-C, FBG, HbA1c, BMI, ACir, body fat percentage, SBP, and DBP. To assess the multicollinearity of the input variables, we investigated the VIF of

TG, HDL-C, LDL-C, body fat percentage, MVALUE). AC Mean and AC Var were 427 included in these 18 variables, suggesting their relatively low multicollinearity with other 428 indices. R^2 of the models that predicted oral DI and clamp DI from the 18 variables were 429 0.64 and 0.50, respectively (Fig. S5A, B). Adj R^2 and AIC of the models that predicted oral 430 DI (Fig. S5A) and clamp DI (Fig. S5B) using both CGM-derived indices and indices from a 431 single-point blood test or physical measurements were better than those of models that used 432 only CGM-derived indices (Figs. S6A, B) or a single-point blood test and physical 433 measurement-derived indices (Fig. S6C, D), indicating that CGM-derived indices in addition 434 to non-CGM indices contribute to a more accurate DI prediction. 435

To avoid overfitting and to investigate the importance of the input variables in 436 predicting DI, we also applied machine learning models, including PLS regression with VIP 437 scores³¹ (Fig. 3C, D) and least absolute shrinkage and selection operator (Lasso) regression³³ 438 (Fig. S7). These regression models have been used for studies where the number of input 439 variables are large relative to the sample size.^{42,43} PLS regression has been used for datasets 440 with mutually correlated input variables and output variable, and important predictors can be 441 estimated by VIP.³¹ Here, high VIP indicates high contribution of the variables in predicting 442 DI. Lasso employs L1 regularization, which leads to models with fewer parameters, and has 443 been used to select useful features to predict DM from numerous input variables.³² 444

The cross validation indicated that the optimal number of PLS components was 2. At
the component, the VIP of some CGM-derived indices, including AC_Var, was higher than 1
(Fig. 3D). The leave-one-out cross validation indicated that the optimal regularization
coefficients of lasso (Lambda) were 0.061 for oral DI and 3.49 for clamp DI (Fig. S7A, B).
At these Lambdas, the coefficients of AC_Var were estimated as non-zero coefficients for
both oral DI and clamp DI (Fig. S7C–F). Collectively, these results indicate that
CGM-derived indices, including AC_Var, contribute to the prediction of DI.

We also investigated the characteristics of AC_Mean and AC_Var in predicting the decreased ability to control blood glucose by conducting random forests and a logistic regression analysis with L1 regularization (Supplementary text 2, Figs. S8–10), suggesting that including AC_Mean or AC_Var alongside conventional indices enhances the accuracy of predicting decreased glucose control abilities.

457

458 Relationship among clinical parameters

To provide an overview of the relationship among indices derived from OGTT, clamp tests, 459 CGM, and other clinical parameters from a single blood test or physical measurements, we 460 constructed a correlation network (Fig. 4). Correlation networks have been used to elucidate 461 462 the interdependency and interconnectivity among different biomarkers of complex metabolic disorders such as T2DM.⁴⁴ In this network, AC_Mean and AC_Var were correlated with 463 some insulin-related indices (blue nodes), but the correlations with other indices (red, 464 magenta, and green nodes) were relatively small. We also applied the Benjamini-Hochberg's 465 multiple comparison test for each comparison, and showed relationships with Q < 0.05 in 466 Table S2. AC_Var was significantly correlated with k_7 , oral DI, and clamp DI (Table S2). 467 Collectively, we conclude that the autocorrelation function of glucose levels has the ability to 468 capture a diminished capacity for blood glucose control that remains undetected by 469 conventional indices. 470

471

472 Validation of the contributions of AC_Mean and AC_Var in predicting a decreased 473 ability to control blood glucose using an independent dataset

To further validate the significance of AC_Mean and AC_Var in predicting reduced blood glucose control capacity, we conducted multivariate analyses (Fig. 5A–D) and constructed a correlation network (Fig. 5E) by using a different dataset.¹⁹ This dataset included 57

participants who were free from prior diabetes diagnosis, with 5 individuals meeting the
criteria for T2DM, 14 having pre-DM, and the remaining participants having NGT.

The assessment of multicollinearity using VIF revealed that AC Mean exhibited 479 relatively low multicollinearity with other indices (Fig. 5A, B), consistent with findings from 480 previous analyses (Fig. 3A, B). The VIF of the indices calculated using the previously 481 reported dataset (VIFp) and those calculated using the dataset obtained in this study (VIFt) 482 were statistically significantly correlated (Fig. 5C), indicating the validity of the relationship 483 among the clinical parameters. The cross validation indicated that the optimal number of 484 components of the PLS regression model predicting SSPG, which indicates insulin sensitivity, 485 was 2. At the component, VIP of AC_Var in predicting SSPG was higher than 1 (Fig. 5D), 486 487 indicating that AC Var contribute to the prediction of SSPG. To avoid overfitting and to investigate the contributions of the input variables in estimating SSPG, we also conducted 488 Lasso (Fig. S11). The leave-one-out cross validation showed that the optimal regularization 489 coefficient, Lambda, was 0.69 (Fig. S11A, B). At the Lambda, the coefficients of AC_Mean 490 and AC_Var were estimated as non-zero coefficients (Fig. S11C), suggesting that AC_Mean 491 492 and AC_Var contribute to the prediction of SSPG.

493 A correlation network showed that AC_Mean and AC_Var were significantly correlated with SSPG (r = -0.36; 95% CI: -0.57 to -0.09 and r = 0.48; 95% CI: 0.23 to 0.68, 494 respectively), but the correlations with other CGM-derived indices were relatively modest 495 (Fig. 5E). We also applied the Benjamini-Hochberg's multiple comparison test for each 496 comparison, and showed relationships with Q < 0.05 in Table S3. Both AC_Mean and 497 AC_Var were significantly correlated with SSPG (Table S3). These results were consistent 498 with the result that AC_Var was significantly correlated with k_4 , which corresponds to 499 insulin sensitivity (Fig. 2A). These results confirm that the characteristics of AC_Mean and 500 AC_Var are reproducible in capturing reduced blood glucose control ability. 501

It is made available under a	CC-BY	4.0 International license .
------------------------------	-------	-----------------------------

502	To investigate the effects of meals on AC_Mean and AC_Var, we calculated the
503	indices using the previously reported CGM data that were collected after consuming
504	standardized meals ¹⁹ (Fig. S12). The standardized meals were about the same in calories, but
505	differed in the amounts of proteins, fat, and fiber: cornflakes and milk (Cereal) were low in
506	fiber and high in sugar, peanut butter sandwiches (Bread and PB) were high in fat and high in
507	protein, and PROBAR protein bars (Bar) were moderate in fat and protein, as previously
508	described. ¹⁹ The previously reported indices, DTW_Low, DTW_Mod, and DTW_Sev, were
509	able to capture the differences in glucose fluctuations due to different meals (Fig. S12A). ¹⁹
510	By contrast, one-way analysis of variance for testing the significance of differences in
511	AC_Mean and AC_Var for each meal showed no significant difference (Fig. S12B),
512	suggesting that AC_Mean and AC_Var were more robust to meal types.
513	
514	AC_Mean and AC_Var capture changes in blood glucose dynamics in the early stage of
515	glucose intolerance
515 516	glucose intolerance To further validate the predictive characteristics of AC_Mean and AC_Var in identifying
516	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying
516 517	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose
516 517 518	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose data. We previously reported that as DI decreases, insulin clearance decreases simultaneously
516 517 518 519	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose data. We previously reported that as DI decreases, insulin clearance decreases simultaneously in the early stage of glucose intolerance. ²⁸ Hence, we evaluated how AC_Mean and AC_Var
 516 517 518 519 520 	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose data. We previously reported that as DI decreases, insulin clearance decreases simultaneously in the early stage of glucose intolerance. ²⁸ Hence, we evaluated how AC_Mean and AC_Var change as DI and insulin clearance decrease simultaneously.
 516 517 518 519 520 521 	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose data. We previously reported that as DI decreases, insulin clearance decreases simultaneously in the early stage of glucose intolerance. ²⁸ Hence, we evaluated how AC_Mean and AC_Var change as DI and insulin clearance decrease simultaneously. For simulation of the mathematical model (see Methods), we used parameters
 516 517 518 519 520 521 522 	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose data. We previously reported that as DI decreases, insulin clearance decreases simultaneously in the early stage of glucose intolerance. ²⁸ Hence, we evaluated how AC_Mean and AC_Var change as DI and insulin clearance decrease simultaneously. For simulation of the mathematical model (see Methods), we used parameters reported as the mean values in NGT. ³⁰ We changed DI ($k_{sec}k_{sen}$) and insulin clearance (k_{cle})
 516 517 518 519 520 521 522 523 	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose data. We previously reported that as DI decreases, insulin clearance decreases simultaneously in the early stage of glucose intolerance. ²⁸ Hence, we evaluated how AC_Mean and AC_Var change as DI and insulin clearance decrease simultaneously. For simulation of the mathematical model (see Methods), we used parameters reported as the mean values in NGT. ³⁰ We changed DI ($k_{sec}k_{sen}$) and insulin clearance (k_{cle}) from one-half to twice the NGT's values (Fig. 6A). As $k_{sec}k_{sen}$ and k_{cle} increased, FBG
 516 517 518 519 520 521 522 523 524 	To further validate the predictive characteristics of AC_Mean and AC_Var in identifying reduced blood glucose control ability, we characterized them using simulated blood glucose data. We previously reported that as DI decreases, insulin clearance decreases simultaneously in the early stage of glucose intolerance. ²⁸ Hence, we evaluated how AC_Mean and AC_Var change as DI and insulin clearance decrease simultaneously. For simulation of the mathematical model (see Methods), we used parameters reported as the mean values in NGT. ³⁰ We changed DI ($k_{sec}k_{sen}$) and insulin clearance (k_{cle}) from one-half to twice the NGT's values (Fig. 6A). As $k_{sec}k_{sen}$ and k_{cle} increased, FBG levels remained unchanged (Fig. 6A, # α), but there was a point at which blood glucose levels

insulin clearance, and AC_Var was negatively correlated with DI and insulin clearance (Fig.2A).

- 530 We also investigated the effects of noise on AC_Mean and AC_Var (Supplementary
- text 3, Figs. 6C, S13 and S14), and found that AC_Var was more robust to noise than
- 532 AC_Mean, consistent with the result that AC_Var exhibited a stronger correlation with DI
- than AC_Mean (Fig. 2A). Moreover, extending the measurement period and decreasing the
- 534 measurement interval of CGM were found to enhance the accuracy of reduced blood glucose
- control ability (Supplementary text 3 and Fig. S14).
- 536

537 Web application for calculating CGM-derived indices

- 538 To easily calculate CGM-derived indices, we developed a web application
- 539 (https://cgm-ac-mean-std.streamlit.app/) that calculates CGM_Mean, CGM_Std, AC_Mean,
- and AC_Var (Fig. S15). This application was implemented in streamlit. In using this
- application, glucose should be measured every 5 min. The application can also run on a local
- 542 machine using the code in GitHub repository
- 543 (<u>https://github.com/HikaruSugimoto/CGM_AC</u>).
- 544

545 **DISCUSSION**

546 In this study, we found that CGM-derived indices, including AC_Mean and AC_Var, were

647 effective in identifying individuals with reduced blood glucose control ability within a

548 population predominantly consisting of individuals with NGT. AC_Mean exhibited a

- significant correlation with insulin clearance, and AC_Var was significantly correlated with
- both insulin clearance and DI. Insulin clearance predicts the incidence of T2DM in non-DM
- subjects,³⁶ and DI predicts the development of future T2DM beyond FBG and PG120.³⁷
- 552 Collectively, these findings suggest that CGM-derived indices, including AC_Mean and
- 553 AC_Var, can identify abnormalities in blood glucose regulation at an early stage, potentially

serving as alternatives to single-point blood tests or OGTT, which have been found to be
 inadequate⁹⁻¹¹ or inconvenient¹² for the screening of pre-DM.

We also predicted DI and glucose dysregulation by using multiple linear regression, 556 PLS regression, Lasso regression, random forests, and logistic regression with L1 557 regularization. DI is suggested to be a predictor of T2DM development,³⁷ and decreases in 558 insulin sensitivity and insulin secretion reportedly precede the onset of T2DM.¹ However, 559 accurate measurement of DI, insulin sensitivity, and insulin secretion are laborious. The 560 prediction models in this study included only indices derived from a single-point blood test, 561 physical examinations, and CGM, which are relatively easy-to-measure variables. Given that 562 the accuracy of the linear regression model with CGM_Std and AC_Var as input variables 563 564 and clamp DI as the objective variable was about the same as the accuracy of predicting clamp DI from oral DI, these relatively easy-to-measure variables may be alternatives to 565 OGTT and clamp tests under some conditions. In this study, we investigated two different 566 datasets, but both datasets were small in size and included only three T2DM subjects (Table 567 S1). The main purpose of this study was not to create a predictor that can be used in clinical 568 settings; rather, this exploratory study showed that reduced blood glucose control ability may 569 570 be predictable using CGM and that AC_Mean and AC_Var can be useful in the prediction. Larger studies are required for more accurate predictions of the abnormalities. 571

AC_Mean and AC_Var exhibited low collinearity with other CGM-derived indices 572 and showed the potential to capture changes in blood glucose dynamics indicative of 573 early-stage glucose intolerance (Figs. 2–5). The mathematical modeling further highlighted 574 their potential in identifying abnormalities even when FBG levels remain unchanged (Fig. 6). 575 Collectively, these results indicate that AC_Mean and AC_Var can capture glycemic 576 disability that cannot be captured by the conventional indices. However, the exact underlying 577 578 mechanisms of these results and their relationship with other CGM-derived indices remain 579 unknown. In this study, we investigated only the mean and the variance of the autocorrelation

function at lags 1–30, relatively well-known CGM-derived indices,²⁵ and three indices that have been reported to identify abnormal glucose regulation.¹⁹ However, the mean and the variance of the autocorrelation function at lags 1–2 (Fig. S4) were also significantly correlated with oral DI (r = -0.29; P = 0.02 and r = 0.29, P = 0.02, respectively), and other CGM-derived indices of glycemic variability have been reported.^{26,45–56} It is necessary to investigate these indices comprehensively to determine the extent to which abnormalities can be identified from CGM in the future.

In conclusion, the current study demonstrated that CGM-derived indices, AC_Mean and AC_Var, can detect decreased blood glucose control ability beyond conventional markers such as FBG, HbA1c, and other CGM-derived indices. Furthermore, the results indicate that CGM could potentially estimate DI, a strong indicator of glucose dysregulation and T2DM onset. This suggests that CGM-derived DI (CGM DI) may serve as an alternative to the labor-intensive measurements involved in conventional DI assessment using OGTT (oral DI)

593 or clamp tests (clamp DI).

594

595 Acknowledgments

596 **Personal Thanks.** We thank Mio Shudo and Yuka Nakamura for their assistance with the

analysis; and our laboratory members for critically reading this manuscript

598 Author Contributions. H.S. analyzed the data. H.S., K.H., T.N., T.Y., H.M., N.O-S., M.F.,

599 Y.H., K.S., W.O., and S.K. wrote the manuscript. T.N., T.Y., H.M, and N.O-S. conducted

clinical examinations. W.O. and S.K. supervised the study.

Data sharing statement. The CGM data that support the findings of this study are available

from the GitHub repository (<u>https://github.com/HikaruSugimoto/CGM_AC</u>). The code that

calculates AC_Mean and AC_Var is also available from the repository

604 (<u>https://github.com/HikaruSugimoto/CGM_AC</u>) and the web application

605 (<u>https://cgm-ac-mean-std.streamlit.app/</u>).

- 606 **Conflict of Interest.** The authors have no competing interests to declare.
- 607 **Funding and Assistance.** This study was supported by the Japan Society for the Promotion
- of Science (JSPS) KAKENHI (JP21H04759), CREST, the Japan Science and Technology
- Agency (JST) (JPMJCR2123), and The Uehara Memorial Foundation.

Figure Legends 610









Fig. 1. Blood glucose fluctuations and correlogram of the time series data. Time courses 612 of blood glucose levels measured by continuous glucose monitoring in two subjects and their 613 614 correlograms. Red lines indicate the mean value of the autocorrelation function (AC_Mean),

- and red shaded areas indicate the variance value of the autocorrelation function (AC_Var) 615
- (see Methods). Lag 1 autocorrelation of blood glucose measurements taken at 5-min intervals 616
- refers to the relationship between the current value (Blood glucose [t]) and the value recorded 617
- one time point later (Blood glucose [t+5x1]). Lag 5 and lag 15 similarly refers to the 618
- relationship between the current value (blood glucose [t]) and the value recorded five time 619
- points later (blood glucose [t+5x5]) and 15 time points later (blood glucose [t+5x15]), 620
- 621 respectively.









testing the hypothesis of no correlation. CGM Mean and CGM Std indicate the mean value 626 and standard deviation of blood glucose levels measured by CGM, respectively. DTW_Low, 627 DTW Mod, and DTW Sev are previously reported indices of glucose variability and glucose 628 dysregulation¹⁹ (see Methods). AC_Mean and AC_Var are the mean and the variance value 629 of the autocorrelation function of blood glucose fluctuations measured by CGM, respectively. 630 The parameters k_4 , k_5 , and k_7 correspond to insulin sensitivity, insulin secretion, and 631 insulin clearance, respectively. (B) Scatter plots for DTW_Sev versus AC_Var. Subjects were 632 colored based on diabetes diagnosis (the left) and the value of clamp DI (the right). This 633 diagnosis is based on the American Diabetes Association Guidelines of HbA1c, fasting blood 634 glucose, and OGTT. An NGT subject who had high AC_Var and high DTW_Sev had low 635 636 clamp DI (*1). Some subjects had low DTW Sev and low clamp DI (*2), and others had low AC_Var and low clamp DI (*3). (C) Hierarchical clustering analysis of the standardized 637 CGM-derived indices using Euclidean distance as a metric with the Ward method. The 638 columns represent the standardized value of DTW_Mod, DTW_Sev, and AC_Var. The rows 639 represent individual subjects. The subjects are grouped and sorted according to their degree 640 of relatedness. (D) Box plots of the value of oral DI and clamp DI for each cluster. Blue, red, 641 green, and magenta are related to clusters 1, 2, 3, and 4, respectively. The boxes denote the 642 median and upper and lower quartiles. Each point corresponds to the value for a single 643 subject. *P < 0.05. Abbreviations: AUC_IRI, area under insulin curve during the first 10 min 644 of hyperglycemic clamp test; CGM, continuous glucose monitoring; DI, disposition index; 645 I.I., insulinogenic index; ISI, insulin sensitivity index; NGT, normal glucose tolerance; 646 OGTT, oral glucose tolerance test; PG120, plasma glucose concentration at 120 min during 647 the OGTT. 648




Fig. 3. Multivariate analyses for predicting the DI. (A) VIF of all variables. (B) VIF of 651

- each variable remaining after removing the variable with the highest VIF one by one until the 652
- VIF of all variables are less than 10. (C) VIP generated from the PLS regression predicting 653
- oral DI. Variables with a VIP ≥ 1 (the dotted line) were considered to be significantly 654
- contributed to the prediction. (D) VIP generated from the PLS regression predicting clamp DI. 655
- Abbreviations: ACir, abdomen circumference; BMI, body mass index; DBP, diastolic blood 656
- pressure; DI, disposition index; FBG, fasting blood glucose; HDL-C, high-density lipoprotein 657
- cholesterol; LDL-C, low-density lipoprotein cholesterol; PLS: partial least squares; SBP, 658
- systolic blood pressure; TC, total cholesterol; TG, triglycerides; VIF, variance inflation 659
- factor; VIP, variable importance in projection. 660




Fig. 4. Correlation network of clinical parameters. A spring layout of the correlation 663 network of 17 CGM-derived indices; 3 blood glucose level-related indices; 9 insulin 664 sensitivity, secretion, and clearance-related indices; and 9 other lifestyle diseases-related 665 indices obtained from a single blood test or physical measurement. Relationship with the 666 absolute values of the Spearman's correlation coefficient of 0.25 or higher are connected with 667 edges. The width of the edges is proportional to the corresponding correlation coefficient. 668 The color of the nodes indicates the type of indices: red, magenta, blue, green is associated 669 with CGM, blood glucose levels, insulin, and other lifestyle-related diseases, respectively. 670 Abbreviations: ACir, abdomen circumference; BMI, body mass index; CGM: continuous 671 glucose monitoring; DBP, diastolic blood pressure; DI, disposition index; FBG, fasting blood 672 673 glucose; HDL-C, high-density lipoprotein cholesterol; I.I., insulinogenic index; ISI, insulin sensitivity index; LDL-C, low-density lipoprotein cholesterol; oral AUC_IRI, area under 674

- insulin curve during the first 10 min of hyperglycemic clamp test; PG120, plasma glucose 675
- concentration at 120 min during the oral glucose tolerance test; SBP, systolic blood pressure; 676
- TC, total cholesterol; TGs, triglycerides. The parameters k_4 , k_5 , and k_7 correspond to 677
- insulin sensitivity, insulin secretion, and insulin clearance, respectively. 678

679







Fig. 5. Validation of the characteristics of AC_Mean and AC_Var using a previously 682 reported dataset. A previously reported dataset¹⁹ was used in this analysis. (A) VIF of all 683 variables. (B) VIF of each variable remaining after removing the variable with the highest 684

VIF one by one until the VIF of all variables are less than 10. (C) Scatter plot for the VIF of 685 the indices calculated using the previously reported dataset (VIFp) versus those calculated 686 using the dataset obtained in this study (VIFt). Each point corresponds to the values for an 687 index. r is Spearman's correlation coefficient and the P value is for testing the hypothesis 688 of no correlation. (D) VIP generated from the PLS regression predicting SSPG. Variables 689 with a VIP ≥ 1 (the dotted line) were considered to be significantly contributed to the 690 691 prediction. (E) A spring layout the of correlation network of 17 CGM-derived indices, 3 blood glucose levels-related indices, 1 insulin sensitivity-related index, 5 other lifestyle 692 diseases-related indices obtained from a single blood test or physical measurement. 693 Relationships with the absolute values of the Spearman's correlation coefficient of 0.25 or 694 higher are connected with edges. The width of the edges is proportional to the corresponding 695 correlation coefficient. The color of the nodes indicates the type of indices: red, magenta, 696 blue, green is associated with CGM, blood glucose levels, insulin, and other lifestyle-related 697 diseases, respectively. Abbreviations: BMI, body mass index; CGM, continuous glucose 698 monitoring; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; 699 700 LDL-C, low-density lipoprotein cholesterol; PLS: partial least squares; SSPG, steady state plasma glucose; TC, total cholesterol; TGs, triglycerides; VIF, variance inflation factor; VIP, 701 variable importance in projection. 702





706 24-h simulated glucose concentration. The color of the line is based on the values of

 $k_{\text{sec}}k_{\text{sen}}$ and k_{cle} . The enlarged views of the areas are shown in $\#\alpha - \#\gamma$. (B) The relationship 707 between $k_{sec}k_{sen}$, k_{cle} and AC_Mean (the left). That of AC_Var is shown in the right. The 708 horizontal axis represents the ratio of $k_{sec}k_{sen}$ and k_{cle} to the reported average values for 709 healthy subjects. (C) AC_Mean (the upper panels) and AC_Var (the lower panels) simulated 710 from the glucose concentration with gaussian white noise. AC_Mean and AC_Var calculated 711 in each trial are shown in the left panels. The distributions of AC_Mean and AC_Var are 712 713 shown in the right. The blue is simulated using the parameters reported as the average values for healthy subjects. The green is simulated at half the average values. The P values are for 714 testing the hypothesis of no difference between the two groups. 715

- Table 1. Multiple regression analyses with oral DI index or clamp DI. (A) Multiple 717

regression analysis between oral DI and CGM-derived indices, DTW_Mod, DTW_Sev, and 718

AC_Var. 719

	Coefficient	SE	Р	95% CI
DTW_Mod	0.029	0.17	0.87	-0.31 - 0.37
DTW_Sev	-0.22	0.17	0.20	-0.56 - 0.12
AC_Var	-0.16	0.071	0.029*	-0.30.017

720

721 (B) Multiple regression analysis between clamp DI and CGM-derived indices, DTW_Mod,

DTW_Sev, and AC_Var. 722

	Coefficient	SE	Р	95% CI
DTW_Mod	7.7	7.1	0.28	-6.4 - 22
DTW_Sev	4.6	7.1	0.52	-9.6 - 19
AC_Var	-7.8	2.9	0.010*	-141.9

723

(C) Multiple regression analysis between clamp DI and CGM-derived indices, CGM_Std and 724

AC_Var. **P* < 0.05 725

	Coefficient	SE	Р	95% CI
CGM_Std	-6.5	3.0	0.035*	-12.50.48
AC_Var	-6.1	3.0	0.048*	-120.05

726

DI, disposition index; CGM, continuous glucose monitoring. 727

References 728

Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk 1 729 state for diabetes development. Lancet 2012; 379: 2279-90. 730 Heianza Y, Hara S, Arase Y, et al. HbA1c 5. 7-6. 4% and impaired fasting plasma 731 2 glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan 732 (TOPICS 3): a longitudinal cohort study. Lancet 2011; 378: 147-55. 733 3 Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired 734 glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-9. 735 4 Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US 736 adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010; 5: 673-737 82. 738 5 Barr ELM, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause 739 mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired 740 glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). 741 742 Circulation 2007; 116: 151-7. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions 743 6 to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic 744 review and meta-analysis. BMJ 2007; 334: 299. 745 Alberti KGMM. Screening and diagnosis of prediabetes: where are we headed? Diabetes 7 746 747 Obes Metab 2007; 9: 12-6. Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug 748 8 and lifestyle intervention following opportunistic screening for pre-diabetes in primary 749 care. Diabetologia 2010; 53: 875-81. 750 Kermode-Scott B. Fasting plasma glucose is inadequate screening test for prediabetes in 9 751 752 obese youth. BMJ 2008; 337: a488. Sumner AE, Thoreson CK, O'Connor MY, et al. Detection of abnormal glucose 10 753 tolerance in Africans is improved by combining A1C with fasting glucose: the Africans 754 in America Study. Diabetes Care 2015; 38: 213-9. 755 Sumner AE, Duong MT, Aldana PC, et al. A1C Combined With Glycated Albumin 11 756 Improves Detection of Prediabetes in Africans: The Africans in America Study. 757 Diabetes Care 2016; 39: 271-7. 758 Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011; 34: 518-23. 759 12 Suh S, Kim JH. Glycemic variability: How do we measure it and why is it important? 13 760 Diabetes Metab J 2015; 39: 273-82. 761 762 14 Tang X, Li S, Wang Y, et al. Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients 763 with well-controlled HbA1c. Clin Chim Acta 2016; 461: 146-50. 764

It is made available under a CC-BY	4.0 International license .

765	15	DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying
766		insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
767	16	Rizos EC, Kanellopoulou A, Filis P, et al. Difference on Glucose Profile From
768		Continuous Glucose Monitoring in People With Prediabetes vs. Normoglycemic
769		Individuals: A Matched-Pair Analysis. J Diabetes Sci Technol 2022; :
770		19322968221123530.
771	17	Hanefeld M, Sulk S, Helbig M, Thomas A, Köhler C. Differences in Glycemic
772		Variability Between Normoglycemic and Prediabetic Subjects. J Diabetes Sci Technol
773		2014; 8: 286–90.
774	18	Keshet A, Shilo S, Godneva A, et al. CGMap: Characterizing continuous glucose
775		monitor data in thousands of non-diabetic individuals. Cell Metab 2023; 35: 758-769.e3.
776	19	Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose
777		dysregulation. PLoS Biol 2018; 16: e2005143.
778	20	Marco A, Pazos-Couselo M, Moreno-Fernandez J, et al. Time above range for
779		predicting the development of type 2 diabetes. Front Public Health 2022; 10: 1005513.
780	21	Miya A, Nakamura A, Handa T, et al. Log-linear relationship between endogenous
781		insulin secretion and glycemic variability in patients with type 2 diabetes on continuous
782		glucose monitoring. Sci Rep 2021; 11: 9057.
783	22	Jin S-M, Kim T-H, Bae JC, et al. Clinical factors associated with absolute and relative
784		measures of glycemic variability determined by continuous glucose monitoring: An
785		analysis of 480 subjects. Diabetes Res Clin Pract 2014; 104: 266–72.
786	23	Chen T, Xu F, Su J-B, et al. Glycemic variability in relation to oral disposition index in
787		the subjects with different stages of glucose tolerance. Diabetol Metab Syndr 2013; 5:
788		38.
789	24	Li C, Ma X, Lu J, et al. Decreasing complexity of glucose time series derived from
790		continuous glucose monitoring is correlated with deteriorating glucose regulation. Front
791		<i>Med</i> 2023; 17 :68–74.
792	25	Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal
793		reference range for mean tissue glucose and glycemic variability derived from
794		continuous glucose monitoring for subjects without diabetes in different ethnic groups.
795		<i>Diabetes Technol Ther</i> 2011; 13 : 921–8.
796	26	Kohnert KD, Heinke P, Vogt L, et al. Declining ss-cell function is associated with the
797		lack of long-range negative correlation in glucose dynamics and increased glycemic
798		variability: a retrospective analysis in patients with type 2 diabetes. Journal of Clinical
799		& Translational Endocrinology 2014; 1: 192–9.
800	27	Thomas F, Pretty C, Dickson J, Signal M, Shaw G, Chase JG. A Simple Method to
801		Model a Continuous Glucose Monitoring Signal. IFAC-PapersOnLine 2017; 50: 8775-
802		80.

porpotate	y.
It is made available under a CC-B	Y 4.0 International license .

803	28	Sugimoto H, Hironaka KI, Yamada T, Sakaguchi K, Ogawa W, Kuroda S. DI/cle, a
804		Measure Consisting of Insulin Sensitivity, Secretion, and Clearance, Captures Diabetic
805		States. <i>bioRxiv</i> 2022: 2022-12.
806	29	Ohashi K, Komada H, Uda S, et al. Glucose Homeostatic Law: Insulin Clearance
807		Predicts the Progression of Glucose Intolerance in Humans. PLoS One 2015; 10:
808		e0143880.
809	30	De Gaetano A, Arino O. Mathematical modelling of the intravenous glucose tolerance
810		test. J Math Biol 2000; 40: 136–68.
811	31	Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics.
812		Chemometrics Intellig Lab Syst 2001; 58: 109–30.
813	32	Wei H, Sun J, Shan W, et al. Environmental chemical exposure dynamics and machine
814		learning-based prediction of diabetes mellitus. Sci Total Environ 2022; 806: 150674.
815	33	Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc 1996; 58:
816		267–88.
817	34	Breiman L. Random Forests. Mach Learn 2001; 45: 5-32.
818	35	Kursa MB, Rudnicki WR. Feature Selection with the Boruta Package. J Stat Softw 2010;
819		36 : 1–13.
820	36	Lee CC, Haffner SM, Wagenknecht LE, et al. Insulin clearance and the incidence of
821		type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. Diabetes
822		<i>Care</i> 2013; 36 : 901–7.
823	37	Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts
824		the development of future diabetes above and beyond fasting and 2-h glucose levels.
825		<i>Diabetes Care</i> 2009; 32 : 335–41.
826	38	Lorenzo C, Wagenknecht LE, Rewers MJ, et al. Disposition index, glucose effectiveness,
827		and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS).
828		<i>Diabetes Care</i> 2010; 33 : 2098–103.
829	39	Gong Z, Chen H. Sequential data classification by dynamic state warping. Knowl Inf
830		Syst 2018; 57 : 545–70.
831	40	Hulman A, Foreman YD, Brouwers MCGJ, et al. Towards precision medicine in
832		diabetes? A critical review of glucotypes. PLoS Biol 2021; 19: e3000890.
833	41	Breschi A, Perelman D, Snyder MP. Response to Hulman and colleagues regarding
834		"Glucotypes reveal new patterns of glucose dysregulation." PLoS Biol 2021; 19:
835		e3001092.
836	42	Pei X, Qi D, Liu J, et al. Screening marker genes of type 2 diabetes mellitus in mouse
837		lacrimal gland by LASSO regression. Sci Rep 2023; 13: 6862.
838	43	Wang C, Kong H, Guan Y, et al. Plasma phospholipid metabolic profiling and
839		biomarkers of type 2 diabetes mellitus based on high-performance liquid

840		chromatography/electrospray mass spectrometry and multivariate statistical analysis.
841		Anal Chem 2005; 77 : 4108–16.
842	44	Huang T, Glass K, Zeleznik OA, et al. A Network Analysis of Biomarkers for Type 2
843		Diabetes. Diabetes 2019; 68: 281–90.
844	45	Matabuena M, Petersen A, Vidal JC, Gude F. Glucodensities: A new representation of
845		glucose profiles using distributional data analysis. Stat Methods Med Res 2021; 30:
846		1445–64.
847	46	Costa MD, Henriques T, Munshi MN, Segal AR, Goldberger AL. Dynamical
848		glucometry: use of multiscale entropy analysis in diabetes. Chaos 2014; 24: 033139.
849	47	Yamamoto N, Kubo Y, Ishizawa K, et al. Detrended fluctuation analysis is considered
850		to be useful as a new indicator for short-term glucose complexity. Diabetes Technol
851		<i>Ther</i> 2010; 12 : 775–83.
852	48	Ogata H, Tokuyama K, Nagasaka S, et al. Long-range negative correlation of glucose
853		dynamics in humans and its breakdown in diabetes mellitus. Am J Physiol Regul Integr
854		Comp Physiol 2006; 291: R1638-43.
855	49	Thomas F, Signal M, Chase JG. Using Continuous Glucose Monitoring Data and
856		Detrended Fluctuation Analysis to Determine Patient Condition: A Review. J Diabetes
857		<i>Sci Technol</i> 2015; 9 : 1327–35.
858	50	Klaus-Dieter K, Heinke P, Vogt L, et al. Indices for assessment of the quality of
859		glycemic control and glucose dynamics from continuous glucose monitoring. Int J
860		<i>Diabetes Clin Res</i> 2017; 4 : 071.
861	51	Crenier L. Poincaré plot quantification for assessing glucose variability from continuous
862		glucose monitoring systems and a new risk marker for hypoglycemia: application to
863		type 1 diabetes patients switching to continuous subcutaneous insulin infusion. Diabetes
864		<i>Technol Ther</i> 2014; 16 : 247–54.
865	52	Rodríguez de Castro C, Vigil L, Vargas B, et al. Glucose time series complexity as a
866		predictor of type 2 diabetes. Diabetes Metab Res Rev 2017; 33. DOI:10.1002/dmrr.2831.
867	53	Peyser TA, Balo AK, Buckingham BA, Hirsch IB, Garcia A. Glycemic Variability
868		Percentage: A Novel Method for Assessing Glycemic Variability from Continuous
869		Glucose Monitor Data. <i>Diabetes Technol Ther</i> 2018; 20 : 6–16.
870	54	Raubertas R, Beech J, Watson W, et al. Decreased complexity of glucose dynamics in
871		diabetes in rhesus monkeys. Sci Rep 2019; 9: 1438.
872	55	Whitelaw BC, Choudhary P, Hopkins D. Evaluating rate of change as an index of
873		glycemic variability, using continuous glucose monitoring data. Diabetes Technol Ther
874		2011; 13 : 631–6.
875	56	Rodbard D. Glucose Variability: A Review of Clinical Applications and Research
876		Developments. <i>Diabetes Technol Ther</i> 2018; 20 : S25–215.
877		